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ABSTRACT
Engineering yeast to evaluate human proteins involved in selective RNA packaging
during HIV particle production
Ryan Matthew Bitter
Despite recent advances in antiretroviral therapy, nearly 37 million people continue to
live with human immunodeficiency virus (HIV). Basic and applied research on the assembly of
HIV could be enhanced by using a genetically tractable organism, such as yeast, rather than
mammalian cells. While previous studies showed that expression of the HIV Gag polyprotein in
Saccharomyces cerevisiae spheroplasts resulted in the production of virus-like particles (VLPs),
many questions regarding the utility of yeast in HIV assembly remain uninvestigated. Here, we
report use of S. cerevisiae for both the production of VLPs with selectively packaged RNA and
to evaluate the human Y-box-binding protein 1 (YB-1) in selective RNA packaging into VLPs.
Our data reveal: (1) When co-expressed alongside HIV-1 Gag, an RNA mammalian expression
cassette is selectively encapsidated and released in VLPs produced from spheroplasts; (2)
Inclusion of the 5’UTR-5’Gag RNA upstream of the mammalian expression cassette greatly
increased the selectivity to which non-viral RNA was packaged into VLPs; and (3) heterologous
expression of the human YB-1 protein in S. cerevisiae did not facilitate the selective packaging
of viral RNA into VLPs, likely due to inability to bind upstream elements in the HIV-1 viral
RNA. Overall, this research provides a key first step in the use of yeast for the production of
viral vectors used in gene therapy, and lays a foundation for further experiments investigating the
role of YB-1 and other host proteins in selective RNA packaging.
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1. INTRODUCTION

1.1 Background
Human immunodeficiency virus (HIV) is estimated to infect nearly 37 million people
worldwide (UNAIDS, 2016). In addition to an increased risk of cardiovascular disease, bone
disease, and cancer, individuals with untreated HIV-infections suffer from CD4 T cell loss,
leading to acquired immune deficiency syndrome (AIDS) (Deeks et al., 2015). Victims of AIDS
are more prone to opportunistic infections and various malignancies, and over 1 million AIDSrelated deaths occur annually (UNAIDS, 2016).

There have been great advances in the efficacy of antiretroviral drugs in recent decades,
resulting in treatments that are effective at inhibiting HIV replication and transmission (Deeks et
al., 2015). However, 19 million HIV-positive people continue to live without treatment due to
associated costs and lack of availability (UNAIDS, 2016). Furthermore, because no drugs
eradicate the virus, those who receive treatment are administered it for their entire lives; This
prolonged use of antiretroviral treatment can result in drug toxicity and the potential for viral
resistance (Freed, 2015).

1.2 Classification
HIV-1 is an enveloped, spherical (80-120 nm diameter), single-stranded positive sense
RNA virus with a double-stranded DNA intermediate. The 9.2 kb ssRNA linear genome is
packaged as a dimer into virions. Characterized by its long incubation period in humans, HIV-1

is a member of the Lentivirus genus, within the Retroviridae family. Based upon genome type
and method of replication, it is in Group VI of the Baltimore classification.

1.3 Viral proteins and their function
The main structural protein of all retroviruses is the Gag polyprotein. HIV-1 Gag is a 55
kDa protein translated on cytoplasmic soluble polysomes (D’Agostino et al., 1992) from
unspliced viral mRNA in the late phase of replication. There are six domains in the Gag
precursor protein. Listed from N- to C-terminus, they are: the matrix (MA), capsid (CA), spacer
peptide 1 (SP1), nucleocapsid (NC), spacer peptide 2 (SP2), and p6 domain (reviewed in Freed,
E.O., 2015). MA is involved in Gag membrane binding and envelope glycoprotein
incorporation; CA is involved in Gag multimerization and assembly and forms the conical core
of virus particles; NC is involved in binding genomic RNA to direct selective packaging into
assembling virions; p6 is required for recruitment of the host endosomal sorting complex
required for transport (ESCRT) machinery, which drives membrane scission for the release of
virions from infected cells. After translation, an N-terminal glycine on MA becomes
myristoylated, a process essential for host membrane binding at the sites of virion assembly
(Bryant and Ratner, 1990).
Heterologous expression of the Gag polyprotein is sufficient to mediate assembly and
release of virus-like particles from a variety of cell types, and this phenomenon is frequently
exploited in experimental systems. However, replication of HIV-1 in naturally-infected human
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cells requires a greater subset of viral proteins in order to produce infectious virions. A
ribosomal frameshift event during Gag translation allows bypass of the stop codon at the end of
Gag and readthrough to the protease, integrase, and reverse transcriptase proteins, thereby
creating a 160 kDa GagPol fusion protein. The viral protease cleaves the domains of Gag and
GagPol into individual proteins, triggering virion maturation. Following infection, reverse
transcriptase converts single-stranded RNA into double-stranded DNA, referred to as proviral
DNA, in the cytoplasm. Integrase is required to insert proviral DNA into the host genome. The
viral envelope (Env) is a single pass, type 2 integral membrane protein translated from singly
spliced mRNA that undergoes glycosylation as it is trafficked through the secretory pathway,
hence it is a glycoprotein (commonly referred to as gp160). A host factor cleaves gp160 near the
C-terminus, resulting in gp41 and gp120. Gp120 is a highly variable surface glycoprotein which
interacts with the viral receptor CD4 (Landau et al., 1988) to mediate attachment to target cells.
Gp41 is a transmembrane protein that contains hydrophobic fusion peptides allowing fusion with
the host cell membrane. The complex interaction between the viral structural proteins and the
cellular factors they co-opt to mediate particle formation is called assembly.

1.4 HIV-1 Assembly
The late phase of HIV replication, which encompasses viral assembly, begins when viral
mRNA is transcribed from proviral DNA in the nucleus. Here, unspliced and incompletely
spliced viral RNA associates with the viral Rev protein, and is exported to the cytoplasm. In the
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cytoplasm, Rev facilitates the localization of gag mRNA on polysomes, allowing efficient
translation of the Gag precursor polyprotein (D’Agostino et al., 1992). After translation, the
glycine residue at position two of the N-terminus of the MA domain is covalently modified by
the addition of a 14-carbon fatty acid called a myristate (Gottlinger et al., 1989). Both the Nterminal myristate and a stretch of basic residues in the MA domain are required for membrane
binding of Gag (Zhou et al., 1994). Interestingly, the myristoylated Gag precursor polyprotein
binds with high affinity to membranes, whereas myristoylated MA domain alone does not. This
observation led to the hypothesis of a “myristoyl switch”, in which myristate exposure is only
triggered under particular circumstances (Zhou and Resh, 1996). Tang et al. (2004) found that
the myristate group is sequestered when MA is in the monomer state, and exposed when MA is
in the trimer state. In other words, the exposure of the N-terminal myristate of MA is dependent
upon the multimerization state of Gag. As Gag polyproteins are brought into close proximity
during assembly, such as when they bind to viral RNA, MA trimerization occurs, followed by
exposure of the myristate group which allows for membrane anchoring (reviewed in Resh,
2004). At the sites of assembly, Gag molecules are arranged with their N-termini in contact with
the membrane and their C-termini oriented towards the center of the immature Gag shell at the
plasma membrane.
Various membrane-bound subcellular compartments within the cell are candidate binding
sites for the N-myristoylated MA domain of Gag. For instance, in epithelial-like 293T cells, Gag
was shown to localize in late endosomes (Figure 1B) (Grigorov et al. 2006). In HeLa cells, Gag
4

can assemble at both the plasma membrane and at late endosomal membranes/ multivesicular
bodies (LE/MVB) (Sherer et al., 2003). Disruption of AP-3, a clathrin-associated
heterotetrameric adaptor protein complex, negatively affects HIV-1 release from HeLa cells,
indicating that LE/MVB may play a role in HIV assembly and release (Dong et al., 2005). In
human macrophages, Gag was shown to be targeted to multivesicular bodies and, despite this,
subsequent release of virions from these cells occurred with high efficiency (Ono and Freed,
2004). It has been proposed that the assembly and subsequent budding of Gag into intracellular
compartments in macrophages allow virions to exit the cell via microchannels (Figure 1C)
(Balasubramaniam and Freed, 2011). In dendritic cells, Gag assembly occurs at points of cell-tocell contact, called virological synapses, where virions are then accessible to filopodia of CD4+
T cells (Figure 1D) (Balasubramaniam and Freed, 2011). Lastly, some researchers contend that
assembly at the plasma membrane occurs in uropod structures (Figure 1E). This localization of
Gag in uropod structures has been observed in polarized T cells, where Gag co-localized with
multiple uropod markers, including CD43 (Llewellyn et al., 2010).

5

Figure 1: HIV assembly at different membrane interfaces (Balasubramaniam and Freed, 2011)

The most widely-accepted site of HIV-1 Gag assembly is the plasma membrane (Figure
2). Assembly at the plasma membrane allows efficient virion release, either extracellularly or
via direct transfer to neighboring cells at points of cell-to-cell contact, called virological synapses
(Balasubramaniam and Freed, 2011). By mutating endosome motility and preventing endosomal
uptake, Jouvenet at al. (2006) found that Gag specifically targets the PM independent of an
endosomal intermediate, and that this targeting to the PM is essential for the production of
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virions. This refuted the models of assembly presented earlier, and corroborated a different
study that used fluorescent imaging to determine Gag is localized at the PM shortly after
synthesis (Rudner et al., 2005). Gag polyproteins are believed to arrive at the PM directly from
the cytosol (Ivanchenko et al., 2009) after being trafficked along microtubule filaments via the
kinesin KIF4 motor protein (Martinez et al., 2008). Once at the PM, N-myristoylated Gag
anchors in the inner leaflet via interactions between MA and the phospholipid
phosphatidylinositol‑(4,5)‑bisphosphate (Ono et al. 2004). This interaction notably occurs in
lipid raft microdomains (Ono et al. 2001), which explains high levels of cholesterol and
sphingolipids in the viral membrane after budding and release (Brugger et al. 2006). The
negatively charged inositol headgroup of PtdIns(4,5)P2 interacts with MA, promoting
multimerization of the CA domain of Gag as the immature Gag lattice forms (Shkriabai et al.,
2006). Although continuous, the immature Gag lattice contains gaps to accommodate curvature
of the icosahedral virion (Briggs et al., 2009). A fully-assembled HIV-1 virion is composed of
~1,500-3000 Gag proteins with about a 20:1 ratio of Gag to GagPol, and spans a diameter of
~120 nm (Freed, E.O. 2015; Lingappa et al. 2014).
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Figure 2: HIV assembly at the plasma membrane, and subsequent release of virions (Freed,
2015)
In contrast to our understanding of Gag assembly, little is known about Env incorporation
into virions. Proposed mechanisms for Env incorporation include either simultaneous targeting
of Gag and Env to lipid rafts in the plasma membrane, or direct recruitment of Env by Gag
(Freed, E.O. 2015). A small deletion near the gp41 cytoplasmic tail disrupts Env incorporation
into virions, while the process is rescued by a single amino acid change in the MA domain of
Gag, indicating Gag-Env interactions mediate envelope incorporation (Murakami Freed, 2000).
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After assembly at the plasma membrane, budding and release of the virion is mediated by
the endosomal sorting complex required for transport (ESCRT). The ESCRT machinery is coopted by the p6 domain of Gag; Specifically, the PTAP motif on the p6 domain of Gag binds the
tumor susceptibility gene 101 (TSG101) subunit of ESCRT-I, and the YPXL motif of p6 binds
an ESCRT-associated factor called Alix. As budding progresses, membrane scission is driven by
ESCRT-III and Vps4 (Freed, E.O. 2015). This results in the release of a virion, allowing
subsequent cleavage by the viral protease to trigger maturation.
While most of our understanding of HIV-1 assembly has been achieved using
mammalian cells, Gag assembly can be reconstituted in vitro using cell-free systems. Campbell
and Rein (1999) showed that Gag assembly in vitro produces 25-30 nm spherical particles,
which is about 5-fold smaller than Gag virus-like particles (VLPs) assembled in vivo. Using
non-viral RNAs and short oligonucleotide DNAs, the authors also showed that nucleic acids
were required for the assembly of Gag with a deleted p6 domain. Most recently, a cell-free
system has been used to recapitulate selective packaging of HIV-1 RNA by Gag using giant
unilamellar vesicles, purified N-myristoylated Gag protein, and viral RNA (Carlson et al., 2016).
These authors found that the 5’ untranslated region (5’UTR) RNA of HIV-1 could be selectively
packaged into Gag VLPs in the context of excess competitor RNA, while mutations in the capsid
C-terminal domain abrogated RNA selectivity. Furthermore, Carlson et al. (2016) showed that
excess tRNA prevented Gag membrane binding unless Gag had already bound viral RNA,
indicating that selective RNA packaging facilitates Gag assembly. As the field progresses, the
9

ability to reconstitute HIV-1 assembly in cell-free systems will likely continue to be used to
verify or refute whether particular components are required at different stages in assembly.

1.5 Host factors involved in HIV assembly
While many descriptions of HIV-1 assembly focus solely on Gag components alone, host
factors co-opted by the virus remain integral in assembly. The first host protein involved in the
late phase of HIV replication is Crm1, a cellular nuclear export receptor that, together with Rev,
exports viral RNA from the nucleus to the cytoplasm (Yi et al., 2002). Multiple cellular factors
have been implicated in trafficking of viral proteins to the assembly site at the plasma membrane.
Kinesin KIF4 is a motor protein involved in Gag trafficking on microtubule filaments towards
the plasma membrane (Martinez et al., 2008). Interestingly, the HIV-1 MA domain of Gag binds
to KIF4, which induces KIF4 to interact with the microtubule end-binding protein EB1, thereby
increasing microtubule stability during the early phase of HIV-1 infection (Sabo et al., 2013).
Additionally, ABCE1, an adenosine triphosphatase, and DDX6, a DEAD box RNA helicase, are
two proteins normally localized in processing bodies (P-bodies) that have been shown to be coopted by HIV. ABCE1 binds Gag to promote multimerization at the plasma membrane, where it
then dissociates upon assembly and release of virions (Dooher et al, 2007). DDX6 was shown to
facilitate immature capsid assembly and is present at numerous assembly intermediate stages
(Lingappa et al., 2014). In terms of facilitating Gag interactions with viral genomic RNA, the
RNA binding protein Staufen 1 is believed to provide a necessary link. A previous study has led
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to the idea that Staufen 1 traffics HIV-1 genomic RNA into nascent virions during assembly,
largely due to the findings that Staufen 1 co-precipitates with unspliced HIV-1 RNA and is
encapsidated into virions (Cochrane et al. 2006). Incorporation of the envelope glycoprotein at
assembly sites is believed to be mediated by TIP47 (tail-interacting protein of 47 kDa), because
TIP47 has been shown to provide the link between Gag and Env (Lopez-Verges et al., 2006).

1.6 Y-box binding protein 1
The Y-box binding protein 1 (YB-1; also known as nuclease-sensitive element-binding
protein 1) is a 324 amino acid protein with a molecular mass of 36 kDa. In humans, the YBX-1
gene is located on chromosome 1. Like other Y-box binding proteins, YB-1 contains an Nterminus rich in alanine and proline (i.e. the A/P domain), a cold shock domain (CSD), and
alternating positively and negatively charged amino acid residues in an elongated C-terminal
domain (Figure 3). The CSD contains Ribonucleoprotein-1 (RNP-1) and Ribonucleoprotein-2
(RNP-2) domains involved in interactions with nucleic acids. The functions of YB-1, which
occur in both the cytoplasm and cell nucleus, are diverse and involve interactions with both
nucleic acids and proteins. YB-1 has been implicated in transcription, DNA repair, mRNA
splicing, and translation (reviewed in Eliseeva et al., 2011).

Figure 3: Y-box binding protein 1 domain organization (Eliseeva et al., 2011).

YB-1 has been implicated as a host factor in many viral processes. For instance, by
activating adenoviral genes under control of promoter E2, YB-1 is believed to mediate
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replication of an adenovirus in the late phase of infection (Holm et al., 2002). Furthermore,
transcription of polyomaviruses is thought to be regulated by YB-1 through interactions with
polyomavirus JCV promoters (Chen and Khalili, 1995; Kerr et al., 1994). Serving an important
role in RNA export, YB-1 was shown to be required for the interaction of viral ribonucleoprotein
complexes to properly export the nucleus of cells infected with influenza virus (Kawaguchi et al.,
2012). Translation inhibition of the dengue virus was shown to occur when YB-1 binds the
dengue virus 3’UTR, suggesting that, in some cases, YB-1 may even have an antiviral effect
(Paranjape et al., 2007). Lastly, mouse mammary tumor virus (MMTV) was shown to have
particle production decrease due to knockdown of YB-1, suggesting YB-1 facilitates assembly,
and, interestingly, the authors found the interaction between Gag and YB-1 to be RNAdependent (Bann et al., 2014). Overall, these studies suggest YB-1 is an important host factor
involved in different stages of replication for a diverse set of viruses.

Previous studies indicate YB-1 may also participate in the replication of HIV-1. For
instance, YB-1 was shown to bind both Tat, the HIV-1 transcriptional transactivator, and TAR,
an RNA sequence at the 5’ end of HIV-1 that forms a unique stem-loop structure and serves as
the binding site for Tat (Ansari et al., 1999). The protein complex formed from YB-1 and Tat
enhanced activation of the HIV-1 promoter, and the interaction between YB-1 and TAR RNA
increases viral gene transcription (Ansari et al., 1999). Furthermore, YB-1 was shown to interact
directly with stem loop 2 (SL2) in the 5’ untranslated region (UTR) of HIV-1 and increased virus
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production by stabilizing viral RNA (Mu et al., 2013). Overexpression of YB-1 in human
embryonic kidney cells has also been linked to an increased titer in retroviral vectors, also due to
stabilizing interactions of YB-1 with viral RNA (Li et al., 2012). A recent study found YB-1
interacts with HIV-1 integrase, playing a crucial role between reverse transcription of the viral
RNA into proviral DNA and nuclear import of proviral DNA (Weydert et al., 2018). In a
proteomic study, YB-1 was shown to interact with the matrix (MA) domain of Gag, although the
assay did not determine what RNA, if any, bridged the interaction (Li et al., 2016). A
subsequent proteomic study used a novel RNA hybridization and mass spectrometry technique to
identify host factors that bind HIV-1 RNA, and YB-1 was among the 189 proteins identified
(Knoener et al., 2017). At this time, the precise role of YB-1 in HIV-1 assembly remains
unknown.

1.7 Yeast: a model system for HIV-1 basic and applied research

1.7.1 Production of recombinant retroviral vectors used in gene therapy
Gene therapy is a technique to treat or prevent genetic diseases by inserting a properly
functioning gene in place of one that is malfunctioning or absent. The potential of gene therapy
to ameliorate genetic disorders was first proposed forty-six years ago (Friedmann and Roblin,
1972). Since then, the effectiveness of gene therapy has been demonstrated in trials against
various diseases including X-linked severe combined immunodeficiency (Hacein-Bey-Abina et
13

al., 2014), Wiskott-Aldrich syndrome (Aiuti et al., 2013), Hemophilia B (Nathwani et al., 2014),
Leber’s Congenital Amaurosis (Simonelli et al., 2010), beta-thalassemia (Persons, 2010), and
metachromatic leukodystrophy (Biffi et al., 2013). These studies highlight the potential of using
gene therapy to treat human disease.

The majority of gene therapy trials utilize retroviral vectors (Merten, 2004).
Lentiviruses, a genus of retroviruses which includes HIV, frequently serve as vectors because
they can infect both dividing and non-dividing cells, and they contain efficient mechanisms of
reverse transcribing ssRNA into dsDNA for integration into the cell genome, which is crucial for
long-term expression (Amado and Chen, 1999). Ironically, it is the exact molecular mechanisms
that render retroviruses so damaging to human health that hold the potential to alleviate human
suffering through gene therapy. In order to turn gene therapy into a practical application, an
efficient means to produce retroviral vectors must be established.

The production of recombinant retroviruses for gene therapy could be enhanced by using
a genetically amenable eukaryotic organism, such as yeast, rather than mammalian cells. Yeast
offer benefits over mammalian cells because they are inexpensive to cultivate, technically
simpler to work with, and easier to perform genetic manipulations (Andreola and Lityak, 2012).
Many important genes, proteins, and biochemical pathways are conserved from yeast to humans.
The baker’s yeast Saccharomyces cerevisiae has been indispensable in the area of biotechnology,
particularly for the large-scale production of insulin to regulate the blood sugar levels of people
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with diabetes. Plasmid-based expression of HIV Gag in yeast led to the production of VLPs
without infectious viral contamination that often plagues preparations from mammalian cell
cultures (Sakuragi et al., 2002). Development of a yeast packaging cell line for large-scale
production of non-pathogenic and high-titer viral retroviral vectors in gene therapy has been
largely unexplored.

1.7.2 Investigation of HIV-1 assembly in yeast
The experimental tractability of yeast, which make it especially amenable to genetic
manipulations and biochemical techniques, was noted in the late 1980’s as the principle reason
this single-celled eukaryote would contribute greatly to basic research in cell biology (Botstein
and Fink, 1988). Since then, yeast have continued to be a model organism that allowed
significant contributions to our understanding of functional genomics, gene expression, protein
trafficking, and cell cycle regulation.

Yeast can serve as a host for replication of plant viruses such as brome mosaic virus,
tomato bushy stunt virus, and cymbidium ringspot virus, as well as for replication of animal
viruses such as flock house virus, nodamura virus, human papillomavirus, and bovine
papillomavirus (reviewed in Zhao, 2017). Although HIV-1 is unable to replicate in yeast,
plasmid-based expression of the HIV-1 Gag protein in S. cerevisiae results in the release of
virus-like particles (VLPs) upon generation of spheroplasts, in which the cell wall is removed
(Sakuragi et al., 2002). Furthermore, these HIV-1 Gag VLPs released from S. cerevisiae
15

spheroplasts were resistant to protease digestion by trypsin unless a delipidizing detergent was
present, indicating the VLPs were completely enveloped by the yeast lipid membrane (Sakuragi
et al., 2002). The Gag protein expressed in yeast is N myristoylated on glycine (Bathurst et al.,
1989), a modification essential in anchoring Gag to the plasma membrane (Bryant and Ratner,
1990) and required for release of HIV-1 virions in both mammalian cells (Göttlinger et al., 1989)
and yeast (Sakuragi et al., 2002). Gag-GFP without N-terminal myristoylation displayed
cytosolic distribution in yeast cells when compared to the punctate plasma membrane
distribution observed in wild type Gag-GFP (Norgan et al., 2012). Furthermore, the
myristoylation mutant Gag-GFP was not detected in extracellular fractions of yeast spheroplasts
putatively containing VLPs (Norgan et al., 2012). Taken together, these studies suggests that
highly conserved genes, proteins, and biochemical pathways shared between yeast and humans
may be exploited to use yeast as a model system for studying HIV assembly.

Despite the notable similarities outlined above, virus-like particle (VLP) assembly and
release in yeast expressing HIV-1 Gag differs from that in human cells, hindering the use of
yeast as a model organism for studying HIV assembly. Notably, budding of HIV-1 Gag VLPs in
yeast was shown to be ESCRT-independent (Norgan et al., 2012), despite its requirement in
mammalian cells. The same study also corroborated previous evidence provided by Sakuragi et
al. (2002) that “late domains” (short peptide motifs such as PTAP, PPXY, and YPXL that recruit
ESCRT machinery) in p6 are not required for incorporation of Gag-GFP into VLPs in yeast, and
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deletion of late domains had no defect on either subcellular localization of Gag-GFP or VLP
budding. Whether S. cerevisiae utilizes an unconventional pathway to release HIV-1 Gag
VLPs, or if assembly occurs at an intracellular compartment like those described above, is
currently unknown.

Another important observations that hinders yeast as a model organism for studying HIV
assembly is that many of the VLPs in yeast appear to be retained in early endosomes. A similar
observation in mammalian cells was reported when artificially high concentrations of
microRNAs are present (Chen et al., 2014). These microRNAs are thought to be interfering with
the normal assembly by outcompeting the viral gRNA for some host protein that is critical for
normal virion production. This barrier to normal HIV assembly in yeast may actually allow
yeast to be a suitable organism to screen various human proteins for their ability to reinstate
proper HIV assembly.

A candidate human protein that may participate in HIV assembly is YB-1, which has no
homolog in the yeast genome. YB-1 has been recently identified as a key player in recruiting
microRNAs and loading them into exosomes via the ESCRT pathway (Shurtleff et al., 2016).
This suggests that YB-1 may divert competitor RNA away from Gag in the cytoplasm, thereby
allowing Gag to more efficiently multimerize and assemble around viral RNA, facilitating proper
assembly. Furthermore, as described earlier in this introduction, the ability of YB-1 to bind
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HIV-1 RNA led us to hypothesize that YB-1 may provide a necessary link between Gag and
HIV-1 RNA throughout the assembly process.

The goals of this thesis research were to: (1) engineer yeast to produce HIV-1 Gag viruslike particles (VLPs); (2) use minimal HIV-1 RNA sequences to direct selective packaging of a
mammalian RNA expression cassette into Gag VLPs; (3) investigate the role of YB-1 in
selective RNA packaging.

Our experimental approach first involved expressing HIV-1 Gag in yeast, and purifying
VLPs released from spheroplasts using ultracentrifugation through a sucrose gradient. An
RNase protection assay was used to determine if a VLP RNA expression cassette, when coexpressed alongside Gag, could be selectively encapsidated and released in VLPs. Lastly, we
used RT-qPCR with RNA extracted from purified Gag VLPs to evaluate the role of YB-1 and
the 5’UTR-5’Gag RNA in selective RNA packaging. This research validates the use of a yeast
system that produces recombinant retroviral vectors with selectively packaged RNA, and lays a
foundation for further experiments investigating the role of YB-1 (and other host proteins) in
HIV assembly.
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2. MATERIALS AND METHODS

2.1 Strains and growth conditions
The Saccharomyces cerevisiae strain SEY6210 (MATa ura3-52 leu2-3,-112 his3-Δ200
trp1-Δ901 lys2-801 suc2-Δ9) was used in this study. SEY6210 was cultured at 30°C in YPD or
the appropriate synthetic drop-out media to select for plasmids carrying yeast genes that
complement deficiencies in the auxotrophic strain. Cloning, selection, and plasmid isolation of
yeast shuttle vectors was performed using Escherichia coli strain MC1061 cultured at 37°C on
lysogeny media with 100 µg/mL ampicillin prior to transformation into yeast.

2.2 Molecular techniques
All primer sequences are listed in Table 1. All enzymes were used in accordance with
the manufacturer’s instructions, unless otherwise indicated. Phusion Flash High-Fidelity PCR
Master Mix (Thermo Scientific) or Platinum SuperFi DNA polymerase (Thermo Scientific) were
used in PCR reactions for plasmid construction. Thermocycling parameters with Phusion were
as follows: Pre-denaturation at 98°C for 10 seconds; 25 cycles of a 2-step protocol with 98°C for
1 second and a combined annealing/extension temperature of 72°C for 15 sec/kb; concluding
with a final elongation at 72°C for 1 minute. Thermocycling parameters with Platinum SuperFi
DNA polymerase were as follows: Pre-denaturation at 98°C for 30 seconds; 30 cycles of 98°C
for 5 seconds, 68°C for 10 seconds, and 72°C for 15 sec/kb; a final elongation at 72°C for 5
minutes. Overlap-extension PCR used a 1:1 molar ratio of each fragment, not exceeding a total
of 10 ng in each reaction. Digestion-independent cloning (D.I.C.) used Phusion Flash Highfidelity PCR Master Mix with 100 ng of vector and a 1:3 molar ratio of vector to insert.
Thermocycling parameters for D.I.C. were as follows: Pre-denaturation at 98°C 10 seconds,
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followed by 15 cycles of 98°C for 1 second and a combined annealing and extension temperature
of 72°C for 2.5 minutes, concluding with a final 72°C extension for 1.5 minutes and 4°C hold.
All constructs cloned in E. coli were isolated using the GeneJET Plasmid Miniprep Kit (Thermo
Fisher). GeneJET Gel Extraction and DNA Cleanup Micro Kit (Thermo Fisher) was used for
PCR cleanup and gel extraction.
Taq DNA polymerase (Promega) was used for both RT-PCR using cDNA template and
colony PCR consisting of cells from a potential clone. Thermocycling parameters for Taq were
as follows: Pre-denaturation at 95°C for 2 minutes; 35 cycles of 95°C for 30 seconds, 55°C for
30 seconds, and 72°C extension for 1 minute/kb; followed by a final extension of 72°C extension
for 5 minutes.
Restriction enzyme digests used FastDigest restriction enzymes (Thermo Scientific), and
occurred at 37°C for 30 minutes for digestion followed by enzyme deactivation at the suggested
temperature and duration. Ligation reactions used T4 DNA ligase (Thermo Scientific), and
involved a 1:3 molar ratio of vector to insert incubated at 22°C for 1 hour for ligation followed
by reaction termination at 70°C for 5 minutes.

2.3 Plasmid Construction
2.3.1 HIV-1 Gag polyprotein (p55)

The source of the HIV-1 gag coding sequence was pGag-EGFP acquired from the NIH
AIDS Reagent Program. The yeast vector for Rev-independent expression of HIV-1 Gag was
constructed as follows: The HIV-1 gag coding sequence was PCR amplified from pGag-EGFP
using Gag-EcoRI-F and Gag-SalI-R. The gag stop codon was omitted from the Gag-SalI-R to
allow read-through to a C-terminal polyhistidine tag upstream of the yeast alcohol
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dehydrogenase (ADH) terminator in the pRS416 vector, thereby creating a Gag-6xHis-tag fusion
protein. The 1.5 kb amplicon was digested with EcoRI and SalI to create cohesive ends for
ligation, as well as DpnI to remove the pGag-EGFP template. The insert was ligated into the 5’
EcoRI-SalI 3’ cloning site in the MCS of pRS416 downstream of the yeast triose-phosphate
isomerase (TPI) promoter for constitutive expression in yeast. After a clone containing the insert
was identified by colony PCR, the final construct was verified by sequencing at a contract lab
(GENEWIZ).

2.3.2 VLP RNA expression cassette for packaging into VLPs

A GeneArt Strings DNA Fragment (Thermo Scientific; see Appendix) was synthesized
with the following components: the HIV-1 5’-untranslated region (5’UTR), a CMV promoter
and SV40 Poly(A) signal flanking a SalI site for cloning reporter genes that will eventually be
monitored in mammalian cells, and the HIV-1 Rev Response Element (RRE). The DNA string
was PCR amplified with 5UTR-SpeI-F and RRE-XhoI-R. The 1.5 kb amplicon was digested
with SpeI and XhoI, and ligated into the 5’ SpeI-XhoI 3’ cloning site of pRS414 downstream of a
yeast translational elongation factor EF-1 alpha (TEF1) promoter for strong constitutive
expression in yeast.
The 5’ half of the gag coding region was cloned into the above construct as follows: The
first 726 bp of gag was PCR amplified from pRS416 Gag-6xHis-tag with DIC-5UTR-Gag-F and
DIC-CMV-Gag-R. These primers contain sequences on the 5’ end that overlap the vector,
allowing the 5’ 726 bp of gag to be stitched between the 5’UTR and CMV promoter. DIC5UTR-Gag-F also contained an AAG instead of AUG translation start codon at the beginning of
gag to prevent expression of additional gag protein. Fragments of the vector were amplified as
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follows: (1) Primers TS315-R and DIC-5UTR-R were used to PCR amplify a 954 bp fragment
consisting of the upstream sequences in the VLP RNA expression cassette; that is, the yeast
TEF1 promoter and HIV-1 5’UTR. (2) Primers DIC-CMV-F and TS315-F were used to PCR
amplify a 1630 bp fragment consisting of the downstream sequences in the VLP RNA expression
cassette; that is, the CMV promoter, SV40 Poly(A), HIV-1 RRE, and CYC1 terminator. All
reactions were digested with DpnI to remove contaminating plasmid template, followed by gel
extraction of the expected-sized amplicon, henceforth referred to by their respective sizes.
The 5’ half of gag was separately stitched to the upstream and downstream vector
sequences of the VLP RNA expression cassette in the following two reactions (1) The 726 bp
and 954 bp fragments were stitched and amplified using TS315-R and DIC-CMV-Gag-R to
generate a 1.68 kb amplicon (2) The 726 bp and 1630 bp fragments were stitched and amplified
using TS315-F and DIC-5UTR-Gag-F to generate a 2.35 kb amplicon. In summary, the 1.68 kb
and 2.35 kb amplicons both contained the 5’ half of gag (726 bp) overlapping. Finally, overlapextension PCR using TS315-F and TS315-R with the 1.68 kb and 2.35 kb fragments generated a
3.3 kb amplicon, which consisted of the entire VLP RNA expression cassette with the 5’ half of
gag inserted between the 5’UTR and CMV promoter.
To clone the modified VLP RNA expression cassette with the additional 5’ gag sequence
into pRS414, digestion-independent cloning (D.I.C) was used. The original pRS414 construct
containing the TEF1-5UTR-CMVp-SalI-SV40Poly(A)-RRE-CYC1 expression cassette was
digested with SpeI and SalI, the vector without the 5’UTR and CMV promoter was gel extracted,
and D.I.C. was used to clone the insert into the vector, as described earlier.
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2.3.3 Y-box-binding protein 1
The source of the human Y-box-binding protein 1 (YBX-1) coding sequence in frame
with an N-terminal c-myc tag was pDESTmycYBX1, provided by Thomas Tuschl (Addgene
plasmid #19878). Myc-YBX1 was PCR amplified from pDESTmycYBX1 using either the
primer pair AscI-mycYBX1-F and BamHI-YBX1-NoStop-R, or the primer pair AscI-mycYBX1F and BamHI-YBX1-R. AscI-mycYBX1-F and BamHI-YBX1-NoStop-R amplified myc-YBX1
without a stop codon to allow read-through to the C-terminal polyhistidine tag upstream
upstream of a yeast alcohol dehydrogenase (ADH) terminator in the pRS416 vector, thereby
creating a myc-YBX1-6xHis-tag fusion protein. AscI-mycYBX1-F and BamHI-YBX1-R
amplified myc-YBX1 with a stop codon. The PCR products were digested with SgsI and
BamHI, followed by gel extraction of the 1.1kb amplicons. SgsI is an isoschizomer of AscI with
the same recognition sequence. Both inserts were separately ligated into the 5’ SgsI-BamHI 3’
cloning site of pRS416 under the yeast TPI promoter for constitutive expression. After
transformation and cloning in E. coli MC1061, the TPI-mycYBX1-ADH expression cassette was
digested from pRS416 using XhoI and NotI, and the 1.7 kb cassette was gel extracted. The
expression cassette was then ligated into the 5’ XhoI-NotI 3’ cloning site in the MCS of pRS315
to generate plasmid pRS315 TPI-mycYBX1-ADH.
2.4 Transformations
Electroporation was used to transform E. coli MC1061. Two microliters of each ligation
were added to 40 µl electrocompetent MC1061 and transferred to a 2mm gap cuvette (Fisher
Scientific). After a single pulse of 2.5 kV, transformants recovered in 500 µl S.O.C. at 37°C for
30 minutes before being plated on lysogeny media with 100 µg/mL ampicillin.
A standard lithium acetate (LiAc) transformation procedure was used to transform yeast
vectors into SEY6210. A 10 mL culture of yeast grown to early log phase (OD600 ≈ 0.5) was
pelleted at 2,400 x g for 3 minutes, washed once with sterile water, and resuspended in 10 mL of
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LiT (100mM LiAc and 10 mM Tris-Cl, pH 7.4) with 10 mM DTT. The cells were incubated
with gentle shaking for 45 minutes, pelleted, and resuspended in LiT by adding 145µl per
transformation. 125µl of cells were gently mixed with 0.5-1 µg plasmid DNA and 5 µl of
herring sperm (10 µg/µl) and incubated for 10 minutes at room temperature. 300 µl of 50%
PEG-LiT was added and gently mixed, and cells were incubated at room temperature with endover-end rotation for another 10 minutes. Afterwards, 15µl of DMSO was added and
transformation tubes were pulse vortexed and immediately placed at 42°C for 5 minutes. Cells
were gently pelleted in a microcentrifuge at 4,000 rpm for 4 minutes, resuspended in 1 mL YPD,
and incubated at 30°C with shaking for 45 minutes. Finally, cells were pelleted in a
microcentrifuge at 5,000 rpm for 1 minute, resuspended in residual YPD, and plated onto
appropriate synthetic drop-out media complemented by the plasmid(s).

2.5 Western Blotting
Whole cell lysates of S. cerevisiae were prepared by adding 1X SDS Sample Buffer with
1.25% Beta-mercaptoethanol to yeast pellets using 40 µl per 2.5 OD units. Next, ¾ volume of
acid-washed glass beads were added, and for a total of two times samples were incubated at
99°C for 3 minutes with shaking, briefly placed on ice, then vortexed for 30 seconds. Beads
were pelleted at maximum speed in a microcentrifuge for two minutes, the supernatant was
collected, and samples were either cooled to room temperature and loaded onto an SDS-PAGE
gel, or stored at -20°C until use. Pellets of virus-like particles (VLPs) isolated via
ultracentrifugation were resuspended in 100 µl of 1X SDS Sample Buffer with 1.25% Betamercaptoethanol and incubated at 99°C with shaking for 4 minutes. Samples were either cooled
to room temperature and loaded into an SDS-PAGE gel, or stored at -20°C until use.
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Proteins were resolved on 12% SDS-PAGE for ~90 minutes at 100 Volts, and transferred
to a nitrocellulose membrane using a submersible tank transfer system. Blocking occurred in 3%
non-fat dry milk in TBS-T (25 mM Tris, pH 7.4; 150 mM NaCl; 0.5% Tween-20) overnight at
4°C with gentle shaking. To detect Gag-6xHis-tag, 1:1000 HisProbe™-HRP Conjugate (Thermo
Scientific) diluted in TBS-T was used. To detect GFP, 1:2000 anti-GFP conjugated to HRP
(Thermo Scientific) diluted in TBS-T was used. To detect myc-YB1, one of the following
probing methods were used: (1) 1:5000 anti-c-Myc conjugated to HRP (Invitrogen) diluted in
TBS-T with 3% non-fat milk or (2) A combination of 1:2000 anti-c-Myc (Sigma) and 1:1000
YB-1 (Cell Signaling Technology) primary antibodies diluted in PBS-T with 5% non-fat dry
milk, followed by 1:2000 anti-rabbit IgG HRP-linked secondary antibody (Cell Signaling
Technology) diluted in TBS-T with 5% BSA. Detection was performed using
chemiluminescence (Pierce ECL Western Blotting Substrate; Thermo Scientific) on a ChemiDoc
XRS+ (Bio-Rad). Band intensity was quantitated on a ChemiDoc XRS+ with Image Lab
software (Bio-Rad), and a t-test was used to compare band intensity among treatments.

2.6 End-point RT-PCR
First-strand cDNA synthesis was conducted in a 20 µl reaction containing 100 pmol
OdTCDS3 (Table 1), 1mM dNTP mix, and 200 U RevertAid Reverse Transcriptase (Thermo
Scientific) with the appropriate amount of reaction buffer. Because regions of the viral RNA are
GC rich with extensive secondary structure, total RNA and OdTCDS3 were first incubated at 65
°C for 5 minutes followed by chilling on ice prior to being added to the cDNA synthesis
reaction. Reactions were incubated at 45°C for 1 hour for transcription followed by 70°C for 10
minutes to terminate the reaction. PCR amplification was conducted with GoTaq DNA
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Polymerase (Promega) as described in the Molecular Techniques section, unless otherwise
indicated (Figure 4).
RT-PCR targeting the VLP RNA expression cassette was conducted with either total
RNA from yeast extracted using the the GeneJET RNA Purification Kit (Thermo Scientific), or
from total nucleic acids extracted from VLPs using the PureLink Viral RNA/DNA Mini Kit
(Invitrogen). To PCR amplify the VLP RNA expression cassette converted to cDNA, GoTaq
DNA polymerase was used as described in the Molecular Techniques section with SpeI-CMV-F
and CDShort and a 52°C annealing temperature. For the ribonucleoprotein (RNP) pull down
assay, PCR amplification to detect the VLP RNA expression cassette converted to cDNA was
performed with GoTaq DNA polymerase using primers RRE-qPCR-F and CDShort, a 53°C
annealing temperature, and 40 cycles.

Figure 4: Schematic representation of RT-PCR used in this study to amplify the VLP RNA
expression cassette. (1) Total RNA from yeast or VLPs was extracted. For simplicity, only
mRNA is shown here. (2-3) First-strand complementary DNA synthesis was performed with
OdTCDS3 and reverse transcriptase. (4) RNase-H activity of reverse transcriptase hydrolyzes
DNA in DNA-RNA duplex. (5-6) In the beginning cycles of PCR, Taq extends the 3’ end of a
primer that anneals to the the CMV promoter in the VLP RNA expression cassette, thereby
creating double-stranded DNA; (7) PCR amplification of the VLP RNA expression cassette.
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2.7 VLP Budding Assay
Yeast transformed with the indicated constructs were grown to OD600 ≈ 0.5. Twenty OD
units were pelleted, resuspended in 3 mL softening buffer (0.1M Tris pH9.4, 10 mM DTT), and
incubated at room temperature with gentle shaking for 10 minutes. Cells were pelleted and
resuspended in 2 mL spheroplasting buffer (1M sorbitol, 3.5 mM DTT, 1X synthetic complete
yeast media with 2% glucose) to which a final concentration of 1 mg/mL Zymolyase 100T (US
Biological) had been added. Digestion of yeast cell walls occurred for 30 minutes at 30°C with
gentle shaking. Spheroplasts were pelleted gently at 500 x g for 3 minutes, resuspended in 2 mL
YPD with 1M sorbitol, and incubated overnight at 30°C with gentle shaking for VLP budding
and release. After overnight (~16 hours) incubation, spheroplasts were pelleted and the clarified
culture supernatant was filtered through a 0.45 micron filter to further exclude remaining
spheroplasts. After filtration, the filtrate was then treated with 50 µg/mL RNase A (Thermo
Scientific) either in the presence or absence of 0.5% Triton X-100 and incubated at 37°C for 30
minutes. Next, 1.8 mL of filtered supernatant were loaded onto 350 µl of 30% sucrose cushion,
and VLPs were pelleted at 45,000 RPM for 2 hours at 4°C in an ultracentrifuge. After
ultracentrifugation, the supernatant was gently removed, being careful to not disturb the VLP
pellet. The VLP pellet was resuspended in 75 µl of PBS and subject to downstream analysis.

2.8 Quantitative RT-PCR
VLP RNA was converted to cDNA as described in the End-point RT-PCR section with
the following modification: 10 µl of 5 ng/µl total RNA extracted from SEY6210 transformed
with pRS416 GFP-6xHis-tag was added to 15 µl of VLP RNA, and 19.5 µl of this combined
RNA was added to a 30 µl reaction with 300 U RevertAid Reverse Transcriptase (Thermo
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Fisher). The addition of total yeast RNA was intended to be an internal control, allowing us to
normalize data by accounting for variability in cDNA synthesis and RT-qPCR between
treatments; However, low qPCR efficiency using the primers intended for this purpose led to us
seeking alternative methods for normalization (e.g., conducting the experiment in three
independent replicates, and determining amount of VLP recovery via quantitative western blot).
RT-qPCR reactions were performed in either 10µl or 20µl reaction volumes with Maxima SYBR
Green/ROX qPCR Master Mix (Thermo Fisher), 0.3 µM RRE-qPCR-F, 0.3 µM CDShort, and 1
µl cDNA. Real-time thermocycling was performed on a CFX96™ Real-Time PCR Detection
System (BioRad Laboratories, Inc.) with the following thermal profile: Initial denaturation 95°C
10 minutes; 40 cycles of 95°C for 15 seconds followed by a combined annealing/extension of
60°C for 1 minute. To create a template for the standard curve, total RNA from yeast expressing
the VLP RNA expression cassette was converted to cDNA, and RT-PCR amplification using
RRE-qPCR-F and CDShort was used to generate the target-sized product. The standard curve
consisted of five consecutive 2-fold serial dilutions of this product.
To determine the relative fold-change in RNA packaged into VLPs due to either the YB1 protein or the 5’UTR-5’Gag RNA, the following equation was used:

Relative fold-change = 2^(ΔCt), where ΔCt = (Ct control - Ct treatment)

“Ct treatment” refers to VLP RNA from yeast expressing the molecule of interest; that is, either
YB-1 protein or the 5’UTR-5’Gag RNA. “Ct control” refers to VLP RNA from yeast not
expressing the molecule of interest.
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2.9 Ribonucleoprotein (RNP) Pull Down
SEY6210 containing the indicated constructs were grown overnight in synthetic drop-out
media and diluted to OD600 of 0.1 in YPD the following morning. Once early log phase growth
(OD600 ≈ 0.35 to 0.5) had been achieved, 30 OD units were pelleted, resuspended in 3 mL
softening buffer (0.1M Tris pH9.4, 10 mM DTT), and incubated at room temperature with gentle
shaking for 10 minutes. Aliquots of 10 OD units were made, pelleted in a microcentrifuge at
5,000 RPM for 1 minute, and cells were then spheroplasted using the procedure described
earlier. Spheroplasts were pelleted in a microcentrifuge at 5,000 RPM for 1 minute, the
supernatant was discarded, and spheroplast pellets were snap-frozen in liquid nitrogen before
being stored at -70°C.
After thawing samples on ice, 600 µl of ice-cold lysis buffer (100 mM HEPES, pH 7.5;
400 mM NaOAc, pH 7.5; 4 mM EDTA; 10 mM MgOAc; 0.25% NP-40; 1X Thermo Scientific
Halt Protease Inhibitor Cocktail) was used to gently resuspend 10 OD units of spheroplasts. For
lysate incubated with HisPur™ Ni-NTA Resin (Thermo Scientific), EDTA was omitted from the
lysis buffer following the manufacturer’s instructions. Samples were sonicated briefly until
noticeable clearing was observed (Setting 5, with a two short pulses of 1-2 seconds) and cellular
debris was removed by centrifugation. Lysate was added to 30 µl Pierce™ Anti-c-Myc Agarose
(Thermo Scientific) for constructs expressing myc-YB1 without a 6xHis-tag, or 60 µl of
HisPur™ Ni-NTA Resin (Thermo Scientific) for constructs expressing myc-YB1-6xHis-tag.
Samples were incubated on an end-over-end rotator for 1 hour at 4°C. The resin containing
bound RNP complexes was gently pelleted in a microcentrifuge at 7,000 RPM for 1 minute at
4°C, and 400 µl of the supernatant containing unbound RNP complexes were stored at -70°C for
later RNA extraction representing the “unbound” fraction. Resin was then washed three times in
700 µl TBS-T and stored at -70°C until downstream analysis.
To extract RNA bound to the resin in RNP complexes, 400 µl of RNP disassociation
solution (1.25 mg/mL Proteinase K; 40 mM DTT) was added to each resin, and samples were
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incubated at 56°C for 15 minutes. To ensure equal treatment of unbound RNP complexes,
Proteinase K and DTT were added to obtain the same final concentrations to unbound samples.
Total RNA was purified from all samples using GeneJET RNA Purification Kit (Thermo
Scientific) and eluted with 100 µl of elution buffer, following the manufacturer’s instructions.
Samples were converted to cDNA and used in RT-PCR as described above.

Table 1: Oligonucleotide primer sequences used in this study. All sequences listed are in the 5’
to 3’ polarity.

Primer Name

Sequence

Tm (°C)

Gag-EcoRI-F

GCCGAATTCATGGGTGCGAGAGCGTCAG

71

Gag-SalI-R

ACGCGTCGACTTGTGACGAGGGGTCGTTGC

73.6

PRS4-Ext-F

TCGACCTTGAGCATGTGG

56

PRS4-Ext-R

CCGGAACGGTATTTGTGC

56

GagEGFP-SalI-R

AGGTCGACTTACTTGTACAGCTCGTCCATG

68.1

5UTR-SpeI-F

GCCACTAGTGGTCTCTCTGGTTAGACCAG

69.5

RRE-XhoI-R

TTTTCTCGAGACTAGCATTCCAAGGCACAGCAG

69.5

DIC-5UTR-Gag-F

GCGGAGGCTAGAAGGAGAGAGAaGGGTGCGAGA
GCGTCAGTATTAAGC

78.8

DIC-CMV-Gag-R

TGACCCCGTAATTGATTACTATTAATAACTAGGTA 73.5
CTAGTAGTTCCTGCTATGTCACTTC

TS315-R

CGACTGGAAAGCGGGCAGTG

63.4

DIC-5UTR-R

TCTCTCTCCTTCTAGCCTCCGC

64

TS315-F

CCATTCAGGCTGCGCAACTG

61.4

DIC-CMV-F

TAGTTATTAATAGTAATCAATTACGGGGTC

59.9

OdTCDS3

GGAACAAAAGCTGGAGCTCTTTTTTTTTTTTTTTV

63.2

CDShort

GGAACAAAAGCTGGAGCTC

56.7
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ENV-EcoRI-F

GCCGAATTCATGAGAGTGAAGGAGAAATATCAG

67

ENV-SalI-R

AGGTCGACTAGCAAAATCCTTTCCAAGCCCTG

69.5

ENV-XmaI-F

CTGCCCGGGACAGAAAAATTGTGGGTCACAG

70.8

ENV-myc-XmaI-R

TGTCCCGGGCAGATCTTCTTCAGAAATAAGTTTTT
GTTCAGCACTACAGATCATCAACATC

75.4

SpeI-CMV-F

GCCACTAGTTAGTTATTAATAGTAATCAATTACGG 67.4
GGTCAT

Act-1 F

CGCTTACTGCTTTTTTCTTCC

55.9

AscI-mycYBX1-F

TTTGGCGCGCCATGGAACAAAAACTTATTTCTGA
AG

68.3

BamHI-YBX1NoStop-R

CCCGGATCCCTCAGCCCCGCCCTGCTCAG

78

BamHI-YBX1-R

CCCGGATCCTTACTCAGCCCCGCCCTGCTCAG

77.2

RRE-qPCR-F

CAGGCAAGAATCCTGGCTG

58.8
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3. RESULTS

3.1 Expression of HIV-1 Gag in yeast
As a first step in creating a yeast system to produce virus-like particles (VLPs), we
sought to express HIV-1 Gag polyprotein in yeast. The HIV-1 Gag coding sequence in-frame
with a C-terminal polyhistidine tag was cloned into pRS416 downstream of a yeast triosephosphate isomerase (TPI) promoter for constitutive expression. After plasmid construction, the
Gag-6xHisTag coding sequence was verified by sequencing (see Appendix). After
transformation into Saccharomyces cerevisiae SEY6210, a western blot of whole-cell lysate
using Ni-HRP to detect the C-terminal polyhistidine tag showed expression of Gag 6xHis-tag as
a protein of the expected size of 55 kDa (Figure 5). To ensure the Ni-HRP, which has high
affinity for histidine residues, was not simply binding an endogenous yeast protein rich in
histidine, SEY6210 transformed with a construct that expressed GFP with a 6xHis-tag instead of
Gag with a 6xHis-tag was analyzed in the adjacent lane. An expected sized band of 28 kDa in
the GFP 6xHis-tag lane was detected, while the 55 kDa protein representing Gag 6xHis-tag was
not detected, indicating the 55 kDa protein in the Gag 6xHis-tag lane was not the result of NiHRP binding an endogenous yeast protein rich in histidine residues.
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Figure 5: Expression of HIV-1 Gag polyprotein in Saccharomyces cerevisiae. Western blot
analysis using Ni-HRP to detect the C-terminal HisTag fused to the HIV-1 Gag polyprotein. As
a control, lysate from yeast that expressed GFP with a HisTag was analyzed in the lane on the
right. Expected sizes: HIV-1 Gag = 57 kDa; GFP = 28 kDa.

3.2 Production of HIV-1 Gag VLPs from yeast spheroplasts
A system for recombinant retroviral vector production is contingent upon efficient
production and isolation of virus-like particles (VLPs). Retroviral VLPs are icosahedral
assemblages of the viral Gag polyprotein that assemble, bud, and are released from cells.
Although VLP budding resembles that of infectious virions, VLPs are non-infectious because
they do not contain necessary viral genetic information or envelope glycoproteins and do not
undergo proteolytic cleavage by the viral protease to trigger maturation into a mature virion.
Once the HIV-1 Gag protein was successfully expressed in yeast, a VLP budding assay
was used to determine if Gag would assemble, bud from the plasma membrane, and be released
from spheroplasts as VLPs. Spheroplasts of SEY6210 transformed with pRS416 Gag-6xHis-tag
were incubated overnight in isotonic medium for VLP budding and release. Next, clarified
culture supernatant was subject to ultracentrifugation through a 30% sucrose cushion to pellet the
VLPs. Lastly, the resuspended ultracentrifuge pellet was analyzed by western blot using Ni-
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HRP to detect the C-terminal polyhistidine tag on Gag. In addition to analyzing the
ultracentrifuge pellet, cell lysates were also analyzed for the presence of Gag. Two necessary
negative controls were included: (1) SEY6210 transformed with pRS416 Gag-6xHis-tag that had
not been converted to spheroplasts (i.e., had an intact cell wall) (2) spheroplasts of SEY6210 that
did not contain pRS416 Gag-6xHis-tag, and therefore were not expressing Gag.
HIV-1 Gag VLPs were detected in the ultracentrifuge pellet of spheroplasts expressing
Gag 6xHis-tag, as evidenced by a 55 kDa protein detected by western blot (Figure 6). Similarly,
Gag was also detected in the lysate of the same culture. Gag was not detected in the
ultracentrifuge pellet of non-spheroplasted yeast, despite its presence in the cell lysate from the
same culture. This provides evidence that VLPs are only efficiently released from yeast
spheroplasts. Spheroplasts that did not contain the Gag construct were void of any similar sized
band in both cell lysate and ultracentrifuge pellet, as expected.

Figure 6: Purification of HIV-1 Gag virus-like particles from Saccharomyces cerevisiae after cell
wall degradation. Western blot analysis using Ni-HRP to detect HIV-1 Gag-6xHisTag in either
the whole-cell lysate or ultracentrifuge pellet (U.P.) of clarified culture media. HIV-1 Gag = 55
kDa.
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3.3 Transcription of VLP RNA expression cassette in yeast
Having observed expression of HIV-1 Gag and production of VLPs in yeast, we next
sought to express a RNA expression cassette that could participate in Gag-mediated selective
packaging into VLPs. A yeast plasmid was constructed that contained the HIV-1 5’-untranslated
region (5’UTR), a cytomegalovirus (CMV) promoter and simian vacuolating virus 40 (SV40)
Poly(A) signal flanking a SalI site, and the HIV-1 Rev Response Element (RRE) (sequence
provided in Appendix). The 5’UTR contains the HIV-1 packaging signal. The purpose of the
CMV promoter and SV40 Poly(A) signal flanking a SalI site is for cloning reporter genes that
will eventually be monitored in mammalian cells after transfection by VLPs. The RRE was
included because it is implicated in HIV-1 genome packaging, as well as export of unspliced and
partially spliced mRNA from the nucleus in the presence of Rev (Kim et al., 1989). This VLP
RNA expression cassette cloned downstream of a yeast translational elongation factor EF-1
alpha (TEF1) promoter for strong, constitutive expression in yeast.
Yeast were transformed with the VLP RNA expression cassette construct containing the
5’UTR, or an identical construct that lacked the 5’UTR; The construct that lacked the 5’UTR
was created in order to evaluate the role of the 5’UTR in later experiments. Total RNA was
extracted and converted to cDNA with OdTCDS3, an oligo-dT with a unique primer sequence
overhanging the 5’ end (referred to as CDS3). First-strand cDNA synthesis with OdTCDS3
results in cDNA linked to the 5’ sequence on OdTCDS3. When paired with a forward primer
complementary to the target cDNA, CDS3 allows PCR amplification of the target cDNA while
avoiding amplification from contaminating DNA, since only a single primer (i.e., the forward
primer) is complementary to contaminating DNA. RT-PCR using CDS3 paired with a forward
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primer targeting the CMV promoter amplified the expected sized band of 1.25 kb from both
constructs (Figure 7). A series of controls were used to verify that the 1.25 kb amplicon was the
result of transcription of the VLP RNA expression cassette. RNA that had not been reverse
transcribed into cDNA (i.e., No-RT control) did not lead to amplification of any detectable
product, indicating the 1.25 kb amplicon was a product of cDNA. Primers that annealed to the
plasmid backbone and CMV promoter were used to determine that plasmid DNA was present in
cDNA, indicating the total RNA extraction had contaminating DNA. However, the primers used
in RT-PCR did not amplify the 1.25 kb product from purified plasmid template, and instead
amplified a ~300 bp fragment (likely the product of non-specific binding), once again showing
CDS3 specificity for cDNA only. Taken together, these data suggest: (1) the primers used in
RT-PCR only amplify a 1.25 kb product from the VLP RNA expression cassette converted to
cDNA and (2) the VLP RNA expression cassette is being transcribed in yeast.

36

A

B

Figure 7: RT-PCR to verify transcription of the VLP RNA expression cassette in yeast. (A)
Diagram showing the template and expected sizes of amplicons from the VLP RNA expression
cassette (top) and contaminating plasmid DNA (bottom). To accommodate text clarity, the
diagram is not drawn to scale. (B) RT-PCR targeting the VLP RNA expression cassette
transcribed in yeast amplified the expected sized band of 1.25 kb (Lane 1 and 2). This 1.25 kb
band was not present in the No-RT control (Lane 3 and 4). Despite the presence of
contaminating plasmid DNA (Lane 5 and 6), the primers used in RT-PCR did not amplify the
1.25 kb band from purified plasmid DNA template, and instead amplified a 300 bp fragment,
likely the product of non-specific priming (Lane 7 and 8).
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While it was long believed the HIV-1 packaging signal in the 5’UTR was the only
requisite for selective packaging of viral RNA into assembling virions, recent evidence suggests
that the efficiency of selective packaging is heavily influenced by downstream viral RNA
sequences (Liu et al. 2017). When expressed downstream of the 5’UTR, the 5’ half of gag
coding sequence was shown to increase selective packaging of non-viral RNA into VLPs from
background levels (1-3%) up to 25% (Liu et al. 2017). Given these recent findings, we used
digestion-independent cloning to insert the 5’ half of gag downstream of the 5’UTR in the
construct expressing the VLP RNA expression cassette, and transcription of this new construct in
yeast was verified by RT-PCR as described above (data not shown). Since the SpeI-CMF-F and
CDS3 primer pair amplified a product of identical size to the amplicon when the 5’ half of gag
was not present, we verified the insertion of this additional sequence in the plasmid by
performing a diagnostic digest with an added restriction site near the end of the gag coding
sequence (data not shown).

3.4 Selective packaging of the VLP RNA expression cassette into HIV-1 Gag VLPs
The nucleocapsid domain of Gag binds the HIV-1 packaging signal, a sequence in the
5’UTR, to direct selective packaging of viral genomic RNA into assembling virions (Freed,
2015). Having produced Gag VLPs from yeast and verified transcription of the VLP RNA
expression cassette, we sought to determine if the VLP RNA expression cassette could be
selectively packaged into Gag VLPs.
A limitation of pelleting VLPs through a sucrose cushion as opposed to sucrose gradient
centrifugation is that it is not possible to separate VLPs from exosomes or other extracellular,
membrane-bound vesicles that contain cellular mRNA. We reasoned that these vesicles, likely
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contaminating our ultracentrifuge pellet, could incorporate the VLP RNA expression cassette,
providing a false positive with RT-PCR if the VLP RNA expression cassette is not packaged into
Gag VLPs. To test this, we determined if the presence of the VLP RNA expression cassette in
the VLP fraction depended on Gag presence, reasoning that if Gag were absent the
ultracentrifuge pellet would not contain the VLP RNA expression cassette. Using spheroplasts
that expressed the VLP RNA expression cassette in the absence of Gag (i.e., Gag VLPs were not
produced from this strain), RT-PCR produced a very faint, barely visible band corresponding to
the VLP RNA expression cassette in the ultracentrifuge pellet (Figure 8). The abundance of the
VLP RNA expression cassette seemed to be near the minimum for detection, even for a sensitive
technique like RT-PCR, and particularly in comparison to when Gag was present (Figure 8).
This suggests the VLP RNA expression cassette is present at extremely low abundance in
exosomes or extracellular vesicles that are pelleted with VLPs, while the predominant source of
the VLP RNA expression cassette in the ultracentrifuge pellet comes from its association with
Gag.
Having determined that the VLP RNA expression cassette in the ultracentrifuge pellet is
associated with Gag rather than contaminating extracellular vesicles, we conducted an RNase
protection assay to determine if the VLP RNA expression cassette was encapsidated in
enveloped Gag VLPs, rather than associated with Gag outside of this context. The rationale
behind the RNase protection assay was that if an RNA is only sensitive to RNase in the presence
of a detergent, then a membrane (i.e., the plasma membrane enveloping a VLP) is protecting the
RNA. Spheroplasts expressing both Gag and the VLP RNA expression cassette were incubated
overnight in isotonic medium for VLP budding and release. Clarified culture supernatant was
passed through a 0.45 micron filter, and equal aliquots were treated with RNase either in the
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presence or absence of a detergent. Samples were then ultracentrifuged through a 30% sucrose
cushion, and the VLP pellet was subject to both RT-PCR and western blot analysis. We found
that the VLP RNA expression cassette could be detected in purified Gag VLPs when a detergent
was not added prior to treatment with RNase (Figure 8). However, when VLPs were treated with
a detergent before treatment with RNase, the VLP RNA expression cassette was no longer
detected in the ultracentrifuge pellet (Figure 8). Western blot analysis to detect Gag in detergenttreated VLPs showed only trace amounts of Gag, indicating the detergent had indeed abrogated
Gag interactions. These data suggest that a membrane is protecting the VLP RNA expression
cassette found in the ultracentrifuge pellet from yeast co-expressing Gag and the VLP RNA
expression cassette, supporting that the RNA is packaged into bonafide Gag VLPs.
Having shown that the VLP RNA expression cassette is packaged into Gag VLPs, we
sought to determine the selectivity to which the RNA was packaged. In addition to RT-PCR
targeting the VLP RNA expression cassette, we also conducted RT-PCR targeting actin mRNA
with the same samples. Actin mRNA was not detected in the ultracentrifuge pellet regardless of
whether Gag was expressed, and despite the detection of actin mRNA from total yeast RNA.
The exclusion of actin mRNA from VLPs supports that packaging of the VLP RNA expression
cassette is selective, to the extent that one particular, highly-abundant cytoplasmic mRNA is not
incorporated into Gag VLPs.
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Figure 8: RNase protection assay showing VLPs produced in yeast contain a selectively
packaged VLP RNA expression cassette. All yeast used in the experiment expressed the VLP
RNA expression cassette, and all VLPs were treated with RNase before ultracentrifugation. In
the indicated lane, a detergent was used to dissolve membranes protecting RNA. All VLP
pellets were also subject to RT-PCR using primers that targeted actin mRNA; As a positive
control to detect actin mRNA, total yeast RNA was used. RT-PCR representative of two
independent replicates. W.B.= Western Blot.

3.5 Expression of YB-1 in yeast
The creation of a yeast system that supports HIV-1 assembly and selective RNA
packaging provided us an opportunity to evaluate host factors that may participate in these
processes. We chose to focus on the human Y-box binding protein 1 (YB-1), which has been
implicated in facilitating retroviral assembly via interactions with viral genomic RNA (Bann et
al., 2014). YBX-1 was cloned into two yeast centromeric vectors and constitutively expressed
under a TPI promoter. One construct expressed YB-1 with an N-terminal c-Myc tag, and the
other construct expressed YB-1 with both an N-terminal c-myc tag and a C-terminal
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polyhistidine tag. Both constructs were verified as being expressed in yeast via western blot
using anti-c-myc conjugated to HRP (Figure 9).

A

B

Figure 9: Expression of YB-1 in Saccharomyces cerevisiae. (A) Western blot analysis using
anti-c-myc conjugated to HRP to detect expression of myc-YB-1 (left) and myc-YB1-6xHisTag
(right) in yeast. Expected size of YB-1 = 55 kDa. (B) Linear depiction of YB-1 fusion proteins
expressed in yeast

3.6 Effects of YB-1 and 5’UTR-5’Gag RNA on selective RNA packaging into VLPs
Having shown Gag-mediated selective packaging of the VLP RNA expression cassette
into VLPs, the effects of the human YB-1 protein and the viral 5’UTR-5’Gag RNA was
evaluated on selective RNA packaging. In addition to HIV-1 Gag, yeast were transformed with
additional plasmids to set up four trials presented in Figure 10. After incubating spheroplasts in
isotonic medium for VLP budding and release, clarified culture supernatant was treated with
RNase to remove RNA not packaged into VLPs. VLPs were then purified and equal aliquots of
the resuspended VLP pellet were analyzed by western blot to detect Gag and quantitative RTPCR to determine the amount of VLP RNA expression cassette packaged into VLPs. The entire
experiment was repeated in triplicate. No major or consistent differences in Gag VLP yield were

42

visually observed by western blot when YB-1 or the 5’UTR-5’Gag RNA was expressed
alongside Gag compared to when those factors were absent (Figure 11A). Using band intensity
data collected with an imaging software, a t-test revealed no significant differences (p-value >
0.19) between treatments (Figure 11B). These results suggest that any differences in RNA
packaging are due to either the 5’UTR-5’Gag RNA or YB-1, since there were no apparent
differences in Gag VLP recovery.

Figure 10: Trials used to determine the role of YB-1 and the 5'UTR-5'Gag RNA in selective
RNA packaging into VLPs. In addition to expressing Gag, yeast expressed one of four presented
combinations of YB-1 and the VLP RNA expression cassette. These strains were used to
evaluate the role of YB-1 and the 5’UTR-5’Gag RNA in selective RNA packaging.
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Figure 11: Gag VLP yield from quantitative RNA packaging experiment. Equal aliquots of
resuspended VLP pellets were subject to both western blot analysis (presented here) or RT-qPCR
(presented later). The purpose of western blot analysis was to ensure that differences in RTqPCR data were due to either the viral 5’UTR-5’Gag RNA or human YB-1 protein rather than
differences in Gag VLP recovery (i.e., experimental error). (A) Western blot detecting the Gag
polyprotein released in VLPs. Ni-HRP was used to detect the C-terminal His-tag on Gag. All
bands correspond to ~55 kDa, the expected size of Gag. (B) Band intensity from the adjacent
blot was quantified using Image Lab Software (Bio-Rad). A t-test showed no significant
differences between treatments (p>0.19). Mean values are depicted in red.

The role of viral RNA elements in selective packaging is widely studied, while no studies
have examined the role of YB-1 in selective packaging, despite the ability of YB-1 to bind the
HIV-1 5’UTR (Mu et al., 2013). We conducted RT-qPCR to quantitate the effects of the
5’UTR-5’Gag RNA and YB-1 in selective packaging of the VLP RNA expression cassette into
VLPs. Primers were designed to amplify the last 300 bp on the 3’ end of cDNA transcribed
from the VLP RNA expression cassette. The forward primer targeted the HIV-1 RRE, and the
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CDS-R reverse primer was shown in Figure 7 to specifically target cDNA. The primer pair was
evaluated for specificity and efficient amplification with agarose gel electrophoresis. Notemplate controls and No-RT controls were evaluated by RT-qPCR to ensure false amplification
or contamination would not confound data from experimental replicates. The entire experiment
was conducted in triplicate. Based upon standard curve analysis, RT-qPCR reaction efficiency
ranged from 93% to 94.7% (mean efficiency=93.7%), and r^2 values ranged from 0.99 to 0.911
(mean r^2 > 0.95). Ct values corresponding to the VLP RNA expression cassette packaged into
Gag VLPs were recorded (Figure 12A). Using these Ct values, we found roughly 38-fold
enrichment of the VLP RNA expression cassette in VLPs when the 5’UTR-5’Gag RNA was
present compared to when it was absent (Figure 12B). This result demonstrates the importance
of the 5’UTR-5’Gag RNA sequences in packaging non-viral RNA into VLPs. YB-1 had a
negligible impact on selective packaging; The VLP RNA expression cassette was packaged into
VLPs at a mean fold-increase of 0.5 when YB-1 was expressed compared to when it was absent
(Figure 12C). YB-1 expression in the particular yeast strain used in the experiment was verified
by western blot analysis (Figure 12D). Since our experiment relied on heterologous expression
of YB-1 in yeast, these observations may be due to a non-functional YB-1 rather than a
negligible role of YB-1 in RNA packaging (see Discussion section).
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Figure 12: Impact of YB-1 and 5’UTR-5’Gag RNA on selective packaging of a mammalian
RNA expression cassette into VLPs produced in Saccharomyces cerevisiae. RT-qPCR was used
to quantitate the VLP RNA expression cassette packaged into purified VLPs. Both the VLP
budding assay and the RT-qPCR were conducted with three independent replicates. Means
depicted in red. (A) Ct values determined by RT-qPCR targeting the VLP RNA expression
cassette packaged into Gag VLPs. (B) Relative RT-qPCR revealed a 38-fold enrichment of the
VLP RNA expression cassette in Gag VLPs when the 5’UTR-5’Gag RNA was upstream the
mammalian RNA expression cassette compared to when it was absent. (C) Relative RT-qPCR
showed an average of 0.5-fold enrichment of the VLP RNA expression cassette in Gag VLPs
when YB-1 was expressed compared to when it was absent. (D) Western blot verifying YB-1
expression in the yeast strain used in the experiment investigating the role of YB-1 in selective
packaging.
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Previous research has suggested that YB-1 interacts with Gag in an RNA-dependent
manner (Bann et al. 2014). The YB-1 responsive element in HIV-1 RNA has been shown to be
the stem loop 2 of the 5’UTR (Mu et al., 2013). Having not observed a difference in selective
packaging in the presence of YB-1, we conducted a ribonucleoprotein (RNP) pull-down assay to
determine if any interaction between YB-1 and the viral sequences of the VLP RNA expression
cassette could be detected. Lysate from yeast expressing YB-1 and the VLP RNA expression
cassette was incubated with anti-c-myc agarose beads to allow binding of mycYB-1, and RTPCR was used to detect the VLP RNA expression cassette in both the unbound and bound
fraction. The VLP RNA expression cassette was detected in the unbound fraction, with only
background levels bound to the anti-c-myc resin (Figure 13). We conducted the same
experiment using the mycYB1-6xHis-tag construct with Ni-NTA and found similar results (data
not shown). It should be noted that western blot analysis was not used to verify YB-1 had
successfully been pulled down. These results indicate that heterologous YB-1 expressed in yeast
does not bind HIV-1 RNA sequences in the 5’UTR, despite what has been reported in
mammalian cells.

Figure 13: Ribonucleoprotein (RNP) pull-down assay to detect interactions between YB-1 and
the 5’UTR-5’Gag RNA sequences of HIV-1. The N-terminal Myc tag on YB-1 was used to bind
YB-1 to an anti-c-Myc resin, and RT-PCR was used to detect the target RNA in both bound and
unbound fractions. Data representative of two independent replicates.
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4. DISCUSSION
Our study identified viral RNA elements important in Gag-mediated selective packaging
of a mammalian RNA expression cassette into membrane-bound VLPs produced in yeast. VLP
production was shown to be dependent on HIV-1 Gag polyprotein expression in yeast
spheroplasts. Packaging was determined to be Gag-mediated because it was dependent upon coexpression of the VLP RNA expression cassette alongside Gag . Packaging of the VLP RNA
expression cassette was selective to the extent that the highly abundant, cytosolic actin mRNA
was not detected in VLPs. This VLP RNA expression cassette was determined to be enclosed
within a membrane because it was only sensitive to treatment with RNase after a detergent was
added. Comparison of packaging efficiency of the VLP RNA expression cassette both with and
without the 5’UTR-5’Gag RNA sequence revealed that inclusion of this viral RNA sequence
upstream of the VLP RNA expression cassette greatly increased its abundance in VLPs. Our
study did not find evidence that heterologous expression of the human YB-1 protein in yeast
facilitates selective packaging of a VLP RNA expression cassette, and this was likely due to the
inability of YB-1 to bind viral RNA sequences present in the expression cassette.
A previous report has demonstrated selective packaging of viral genomic RNA into Gag
VLPs produced in yeast (Tomo et al., 2013). These authors showed that selective packaging was
greatly dependent on the R-U5-SL region of HIV-1 RNA, and that HIV-1 genomic RNA was
present in VLPs at a 500-fold increase compared to its presence in cells. Because our research is
aimed at producing recombinant retroviral vectors that could be used in gene therapy, we were
interested in only including the minimal HIV-1 RNA sequence necessary to facilitate selective
packaging. A recent study utilizing mammalian cells showed that in addition to the 5’UTR,
which contains the HIV-1 packaging signal, the 5’ half the Gag is important in packaging
reporter genes into VLPs (Liu et al. 2017). Given the indirect impact of downstream sequences
on RNA packaging, it would be interesting to know the effect of our mammalian RNA
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expression cassette on selective RNA packaging when compared to the full-length HIV-1
genomic RNA.
The cytomegalovirus (CMV) promoter included in our VLP RNA expression cassette,
while intended to drive transcription of reporter genes in mammalian cells, has actually been
shown to be active in yeast (Becskei et al. 2001). Due to the location of the CMV promoter in
our VLP RNA expression cassette, it is possible that mRNA transcripts that lacked the 5’UTR5’Gag RNA were generated from the plasmid containing, and intended to express, the 5’UTR5’Gag RNA. We have not found any literature on the activity of the simian vacuolating virus 40
(SV40) polyadenylation site in yeast. In addition to amplifying the expected 1.25 kb fragment
with RT-PCR targeting the VLP RNA expression cassette, we consistently observed
amplification of a smaller band which could have corresponded to one of the above scenarios. It
is unknown how these possibilities could have affected our RT-qPCR results that aimed to
quantitate the impact of the 5’UTR-5’Gag RNA on selective packaging, since the forward
primer targeted the downstream Rev Response Element (RRE) in the VLP RNA expression
cassette. While the HIV-1 RRE has been shown to bind Gag (Carlson et al. 2016), it was
surprising to see the VLP RNA expression cassette that lacked the 5’UTR-5’Gag RNA yet
contained the RRE was packaged into VLPs, albeit with much less affinity than when it was
present.
The HIV-1 genomic RNA has been shown to support the assembly of Gag intermediates
at the plasma membrane (Yang et al. 2018). Additionally, evidence suggests that the
localization of gag-pol mRNAs regulate the site of virion assembly (Becker and Sherer, 2017).
It would be interesting to know if the viral RNA sequence expressed alongside Gag in this study
facilitated VLP assembly and release, perhaps by nucleating Gag assembly and facilitating GagGag multimerization either in the cytosol or at the plasma membrane.
A candidate human protein we examined that may participate in selective packaging of
HIV-1 RNA into VLPs was the human Y-box-binding protein 1 (YB-1). Our attention was first
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drawn to YB-1 because its involvement in recruiting microRNAs into exosomes (Shurtleff et al.
2016). Retention of Gag in endosomes has been reported in mammalian cells when artificially
high levels of microRNAs are present (Chen et al. 2014). Similarly, using previously published
fluorescence microscopy images of Gag-GFP localization during assembly (Norgan et al. 2012),
we observed that Gag VLPs in yeast appeared to be retained in endosomes. We reasoned that
yeast are missing a homolog of a critical host protein required for normal HIV-1 assembly,
particularly by facilitating Gag-RNA interactions. Interestingly, there is no YB-1 homolog in the
yeast genome. Our excitement grew as we read reports of direct involvement of YB-1 in HIV-1
replication via RNA interactions. For instance, YB-1 was shown to interact directly with the
HIV-1 genomic RNA (Knoener et al. 2017), supporting previous studies that mapped the YB-1responsive elements to be both the the SL2 (Mu et al. 2013) and TAR (Ansari et al., 1999)
located in the 5’UTR of unspliced HIV-1 genomic RNA. Furthermore, YB-1 was shown to
increase VLP production of retroviral vector systems via RNA interactions (Bann et al. 2014;
Mu et al. 2013).
We did not observe a functional role of YB-1 in selective packaging of RNA into Gag
VLPs. Despite the observed 0.5-fold increase in selective RNA packaging in the presence of
YB-1, this small increase lies within the range of experimental error. Furthermore, the
ribonucleoprotein (RNP) pull-down assay did not detect an interaction between viral sequences
on the VLP RNA expression cassette and YB-1, despite how YB-1 has been previously shown to
bind the 5’UTR in mammalian cells (Mu et al., 2013). The most likely explanation for the
observed differences in YB-1 protein function in yeast compared to mammalian cells is that posttranslational modifications to YB-1 required for functionality in HIV-1 assembly are not
occurring. In particular, these modifications may affect protein folding that are required for
function. There are numerous residues in YB-1 that are phosphorylated in mammalian cells that
may affect protein folding required for function (reviewed in Prabhu et al. 2015b). The coldshock domain (CSD; amino acid residues 51-129) of YB-1 is the region responsible for RNA-

50

binding, which may impact binding of YB-1 to HIV-1 RNA. Activated Akt phosphorylates YB1 at Ser102 (Dunn et al, 2005). Sch9 (AGC family kinase) is a yeast homolog to Akt (Fabrizio et
al. 2001). Ser165 of YB-1 is also known to be phosphorylated, and it is hypothesized to occur
by casein kinase II (CKII) (Prabhu et al. 2015a). Yeast contain the casein kinase 2 catalytic
subunit (CKA2). It remains to be seen if YB-1 is modified by these homologs in a way that
render it functional, or if upstream activation of these kinases modulating activity of YB-1 is
occurring in yeast. Current research in the Black lab is attempting to change the primary
structure of YB-1 to hopefully mimic folding that occurs when various serine residues are
phosphorylated.
Conversely, there could be post-translational modifications to YB-1 rendering the protein
inactive occurring in yeast. For example, poly-ubiquitination of YB-1 at the sites of Gag VLP
assembly (i.e., the plasma membrane) would trigger multivesicular body (MVB) biogenesis via
nearby ESCRT machinery, leading to degradation of YB-1 in the proteasomal pathway. If polyubiquitination of YB-1 is occurring, this may explain some of our difficulty in detecting a strong
signal for YB-1 on western blots analyzing total yeast lysate, compared to other exogenous
proteins expressed under the same promoter (data not shown).
Since YB-1 is a known constituent of stress granules, P-bodies, exosomes and, at times,
imported into the nucleus (all reviewed in Eliseeva et al. 2011), the HIV-1 RNA in the cytosol
may not be accessible to YB-1 in yeast. Furthermore, YB-1 binding to endogenous yeast
proteins not present in mammalian cells may hide the active site required for function in HIV-1
assembly. Lastly, the interaction between YB-1 and HIV-1 RNA may be bridged by another,
unknown, protein or part of a larger protein complex that is present in mammalian cells but not
in yeast.
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APPENDIX

i. CRISPR-Cas9 genome integration of Gag-eGFP in Saccharomyces cerevisiae
Our first effort to express the HIV-1 Gag polyprotein in Saccharomyces cerevisiae
utilized CRISPR-Cas9 genome integration through homology-directed repair. The lithium
acetate transformation was used to transform SEY6210 with the following three plasmids: (1)
pRS414-Cas9 (provided by George Church; Addgene plasmid # 43802), a construct that
constitutively expressed Streptococcus pyogenes Cas9 under a yeast translational elongation
factor EF-1 alpha (TEF1) promoter; (2) pRPR-gRNA (created by Ben Lewis, CIRM M.S.
thesis), a construct created that expressed a 20-bp protospacer RNA targeting the PRS4 locus; (3)
pHDR-GagEGFP (previously created by undergraduates in the Black lab), a construct that
contained Gag-eGFP under a TEF1 promoter and yeast cytochrome c (CYC1) terminator flanked
by 5’ and 3’ homology arms complementary to the regions of the double-stranded break (DSB)
in the PRS4 locus. Transformants were plated on SD-LEU/-TRP media, and colony PCR using
primers Gag-EcoRI-F and PRS4-Ext-R was used to identify CFUs with GagEGFP integration at
the PRS4 locus.
The TEF1-Gag-eGFP-CYC1 expression cassette was integrated into the yeast genome at
the PRS4 locus, as determined by PCR using genomic DNA of a CRISPR transformant (Figure
14A, 14B). However, the Gag-eGFP protein was not detected on a western blot using anti-GFP
antibodies, despite the detection a GFP positive control (Figure 14C). Because the matrix (MA)
domain of Gag is involved plasma membrane binding, separate fractions of small, water soluble
proteins (i.e. the supernatant from whole-cell lysate) and proteins pelleted with cellular debris
including membranes (i.e. the pellet from whole-cell lysate) were both analyzed by western blot.
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As an alternative approach to determine if the Gag-eGFP fusion protein was expressed, CRISPR
transformants were viewed with fluorescent microscopy. The enhanced GFP protein was not
detected with fluorescent microscopy, corroborating the western blot results that the Gag-eGFP
fusion protein was not being expressed (data not shown).

A

B

C

Figure 14: CRISPR-Cas9 genome integration of GagEGFP under a TEF1 promoter and
upstream of a CYC1 terminator, inserted into the PRS4 locus of the yeast genome. (A) PCR
using genomic DNA from a yeast CRISPR transformant. Primer sequences are listed in
Materials and Methods section; Numerical representations: (1) PRS4-Ext-F (2) Gag-EcoRI-F (3)
GagEGFP-SalI-R (4) PRS4-Ext-R. (B) Diagram showing template and expected amplicon sizes
after CRISPR/Cas9 insertion of TEF1-Gag-eGFP-CYC1 expression cassette into the PRS4 locus.
(C) Western blot analysis using anti-GFP to detect expression of Gag-eGFP from a CRISPR
transformant.
Despite CRISPR-Cas9 integration of the TEF1-Gag-eGFP-CYC1 expression cassette into
the PRS4 locus of the yeast genome, we did not observe Gag-eGFP protein expression.
Similarly, Gag-eGFP amplified from the mammalian pGag-eGFP construct was cloned into a
yeast expression vector downstream of a yeast TPI promoter and, again, expression was not
observed by western blot (data not shown). Gag-GFP has been expressed in yeast with no issue
regarding cleavage of Gag away from GFP (Norgan et al. 2012) and, regardless, we did not
observe any GFP expression. Since the same yeast vector backbone and pGag-eGFP template
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was eventually used to successfully express the Gag-6xHis-tag protein used in VLP production,
the most likely reason for failed expression of Gag-eGFP is an undefined error in the eGFP gene
or sequence linking Gag to eGFP. For instance, a stop codon between Gag and eGFP could
explain why a functional Gag coding sequence was cloned into a yeast vector, but Gag fused to a
C-terminal GFP was not expressed. Additionally, a frameshift mutation after the Gag coding
sequence would lead to the same result. Since antibodies raised against Gag were never used, so
we cannot say with certainty that a functional Gag protein was expressed from the Gag-eGFP
construct; However, we sequenced the Gag coding region in the yeast expression vector and
found the sequence to be correct.

ii. Sequencing Results
The coding region of HIV-1 Gag with a C-terminal 6xHisTag, cloned into pRS416 and
used extensively throughout this study, was verified by sequencing at a contract lab
(GENEWIZ). The sequence in 5’ to 3’ polarity is as follows:
ATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGAAAAAAT
TCGGTTAAGGCCAGGGGGAAAGAAGAAGTACAAGCTAAAGCACATCGTATGGGCA
AGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAGG
CTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAGGAGC
TTCGATCACTATACAACACAGTAGCAACCCTCTATTGTGTGCACCAGCGGATCGAGA
TCAAGGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAGTCCAA
GAAGAAGGCCCAGCAGGCAGCAGCTGACACAGGACACAGCAATCAGGTCAGCCAA
AATTACCCTATAGTGCAGAACATCCAGGGGCAAATGGTACATCAGGCCATATCACCT
AGAACTTTAAATGCATGGGTAAAAGTAGTAGAAGAGAAGGCTTTCAGCCCAGAAGT
GATACCCATGTTTTCAGCATTATCAGAAGGAGCCACCCCACAGGACCTGAACACGA
TGTTGAACACCGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATC
AATGAGGAAGCTGCAGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCTATTGC
ACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACC
CTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATCCCAGTAGGAGAGAT
CTACAAGAGGTGGATAATCCTGGGATTGAACAAGATCGTGAGGATGTATAGCCCTA
CCAGCATTCTGGACATAAGACAAGGACCAAAAGAACCCTTTAGAGACTATGTAGAC
CGGTTCTATAAAACTCTAAGAGCTGAGCAAGCTTCACAGGAGGTAAAAAATTGGAT
GACAGAAACCTTGTTGGTCCAAAATGCGAACCCAGATTGTAAGACCATCCTGAAGG
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CTCTCGGCCCAGCGGCTACACTAGAAGAAATGATGACAGCATGTCAGGGAGTAGGA
GGACCCGGCCATAAGGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTC
AGCTACCATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGATTGTTAAGT
GTTTCAATTGTGGCAAAGAAGGGCACACAGCCAGAAATTGCAGGGCCCCTAGGAAA
AAGGGCTGTTGGAAATGTGGAAAGGAAGGACACCAAATGAAAGATTGTACTGAGA
GACAGGCTAATTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGAAGGCCAGGGAAT
TTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGG
GGTAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATC
CTTTAACTTCCCTCAGATCACTCTTTGGCAACGACCCCTCGTCACAAGTCGACCTGC
AGCCAAGCCACCACCACCACCACCACTAA

iii. GeneArt Strings DNA Fragment for VLP RNA expression cassette
In creating a yeast vector that expressed the VLP RNA expression cassette, we used
GeneArt Strings DNA Fragment service (Thermo Fisher Scientific) to synthesize a linear dsDNA
containing the HIV-1 5’-untranslated region (5’UTR), a cytomegalovirus (CMV) promoter and
simian vacuolating virus 40 (SV40) Poly(A) signal flanking a SalI site, and the HIV-1 Rev
Response Element (RRE). The sequence we ordered is presented in Table 2. (Note: This does
not contain the 5’ half of gag coding sequence downstream of the 5’UTR because that sequence
was cloned in later.) Importantly, given the technology used to synthesize this oligonucleotide of
considerable length, the manufacturer required certain changes me made in the sequence, which
deviated from the “wildtype” version of these genes. Those changes are identified in Table 2,
and the prior nucleotide that occupied that position is presented in Table 3.
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Table 2: GeneArt Strings DNA Fragment (Thermo Fisher Scientific) synthesized for the VLP
RNA expression cassette. The entire fragment was synthesized as a single (1,524 bp) linear
dsDNA in the following order (5’ to 3’): 5’UTR-CMV-SalI- SV40Poly(A)-RRE.

Table 3: Mutations in the VLP RNA expression cassette required by GeneArt Strings DNA
Fragments (Thermo Fisher Scientific) for synthesis. Modifications to the CMV promoter
occurred in the enhancer region (which spans nucleotides 59-465) and did not occur in either the
TATA box (nucleotides 554-560) or Transcription Start Point (583).
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iv. Yeast Expression Vector: HIV-1 Envelope (gp160)
Retroviral vectors in used gene therapy must first attach to and fuse with target cells
before therapeutic genes can be delivered. In HIV-1 replication, attachment and entry is
mediated by the envelope glycoprotein. After gp160 proteolytic cleavage, gp120 binds CD4
receptors on the surface of T cells, allowing coreceptor (CCR5 or CXCR4) binding and
subsequent exposure of the fusion peptide of gp41. Having created a yeast system that produces
Gag VLPs with selectively packaged RNA, we constructed a yeast expression vector to express
the HXB2 envelope (gp160) protein.
The source of the HIV-1 envelope (gp160) coding sequence was pHXB2-Env acquired
from the NIH AIDS Reagent Program. The HIV-1 envelope coding sequence was PCR
amplified from pHXB2-Env using ENV-EcoRI-F and ENV-SalI-R using the thermocycling
profile described for Phusion DNA polymerase, except with a 58°C annealing temperature. The
2.6 kb amplicon was gel extracted and digested with EcoRI and SalI to create cohesive ends for
ligation, as well as DpnI to remove residual pHXB2-Env template. The insert was then ligated
into the 5’ EcoRI-SalI 3’ cloning site in the MCS of pRS416 after dephosphorylation of the
vector with alkaline phosphatase. After transformation, cloning, and plasmid isolation, the TPIENV-HisTag-ADH expression cassette was digested from pRS416 using XhoI and XbaI. The
3.2 kb expression cassette was gel extracted and ligated into the 5’ XhoI-XbaI 3’ cloning site in
the MCS of pRS315. Since the envelope protein is trafficked through the secretory pathway, we
reasoned that a c-Myc tag upstream of the signal peptide may interfere with ER translocation and
protein orientation. Therefore, we inserted the c-Myc tag immediately downstream of the signal
sequence in-frame with the N-terminus of gp120. To add an N-terminal c-Myc tag to gp120
after the signal peptide, pRS315 TPI-ENV-HisTag-ADH (described above) was used as a
template in the following two PCR reactions: (1) ENV-XmaI-F and TS315-F were used to
amplify a 2.9 kb fragment (2) ENV-myc-XmaI-R and TS315-R were used to amplify a 736 bp
fragment. The two fragments were ligated together using a total of ~500 ng DNA in the ligation
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and the 3.6 kb fragment corresponding to the TPI- SS-Myc-ENV-HisTag-ADH expression
cassette was gel extracted to isolate it from other products from the ligation. PCR with TS315-F
and TS315-R was then used to amplify the entire expression cassette for D.I.C. To prepare a
vector for D.I.C., the TPI promoter and ENV coding sequence (without the c-Myc tag) of
pRS315 TPI-ENV-HisTag-ADH was cut out with XhoI and SalI, and the 6.2 kb vector
corresponding to pRS315 was gel extracted. D.I.C. was then used to insert the TPI-SS-MycENV-HisTag-ADH expression cassette into the pRS315 using the thermocycling profile outlined
above for D.I.C., except with a final 72°C extension time of 5 minutes. The final pRS315 TPISS-Myc-ENV-HisTag-ADH construct contains a LEU2 auxotrophic marker so it can be
expressed alongside pRS416 TPI-Gag-HisTag-ADH, which carries a URA3 marker. A
diagnostic restriction digest revealed that the construct was indeed as expected (Figure 15).
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Figure 15: HIV-1 Envelope (gp120) plasmid validation. (A) Diagram of the TPI-SS-Myc-ENVHisTag-ADH expression cassette cloned into pRS315, including restriction sites used in the
diagnostic digest (B) Diagnostic digest of pRS315 TPI-SS-Myc-ENV-HisTag-ADH. The
expected band sizes upon incubation with BamHI and EcoRI is 6505 bp and 2718 bp, while
additionally including XmaI (which is inserted with the c-Myc tag) generates expected band
sizes of 6505 bp, 2166 bp, and 552 bp.
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